New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 17, 2014
12:25 EDTICPT, ICPT, ICPT, GILD, GILD, GILD, RPTP, RPTP, RPTP, CNAT, CNAT, CNATSummer Street biotech analyst to hold an analyst/industry conference call
Specialty Pharma & Biotech Analyst Molloy and Chief Scientific Officer Classen, along with an MCRI consultant, provide a preview of Intercept Pharmaceuticals upcoming FLINT trial data from the NIH in July on an Analyst/Industry conference call. Relevant companies ICPT, GILD, RPTP and CNAT may be included on the Analyst/Industry conference call to be held on June 17 at 1 pm.
News For ICPT;GILD;RPTP;CNAT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
April 26, 2015
14:56 EDTGILDGilead reports 'high cure rates' for Sovaldi in genotype 2-5 hep C patients
Subscribe for More Information
April 24, 2015
09:37 EDTGILDActive equity options trading on open
Subscribe for More Information
08:33 EDTGILDGilead May weekly volatility elevated into Q1 and outlook
Subscribe for More Information
April 23, 2015
16:01 EDTGILDOptions Update; April 23, 2015
Subscribe for More Information
07:59 EDTGILDMylan launches generic sofosbuvir tablets in India
Subscribe for More Information
07:19 EDTCNATConatus results at EASL meeting support emricasan registration pathway in NASH
Conatus Pharmaceuticals announced that posters providing detailed results from four recently completed clinical trials of emricasan, the company's first-in-class, orally active pan-caspase protease inhibitor, are being presented this week at The International Liver Congress 2015. Results from the company's Phase 2 double-blind, placebo-controlled clinical trial of emricasan in patients with acute-on-chronic liver failure, or ACLF, and Phase 2 double-blind, placebo-controlled clinical trial of emricasan in patients with nonalcoholic fatty liver disease, or NAFLD, including the subset of NAFLD patients with nonalcoholic steatohepatitis, or NASH, are addressed in two late-breaker posters. Conatus intends to include NASH-driven cirrhosis in its initial registration strategy for emricasan.
05:44 EDTICPTIntercept FLINT trial data shows OCA treatment increases fibrosis resolution
Subscribe for More Information
05:19 EDTGILDGilead Harvoni, Sovaldi demonstrate efficacy, safety
Gilead Sciences announced results from several Phase 2 clinical studies evaluating investigational uses of Harvoni and other Sovaldi-based regimens for the treatment of chronic hepatitis C virus, or HCV, infection in patients with advanced liver disease, including patients with decompensated cirrhosis, patients with fibrosing cholestatic hepatitis C and patients with portal hypertension. In SOLAR-2, 328 genotype 1 or 4 HCV patients with decompensated liver disease before liver transplantation or recurrent HCV infection following liver transplantation were randomized to receive either 12 or 24 weeks of Harvoni plus ribavirin. Ten patients were excluded from the analysis because of transplantation or because they were pre-transplantation, but not decompensated; an additional 27 of these patients have not yet reached post-treatment week 12. The most common adverse events were fatigue, anemia, nausea and headache. Overall, six patients discontinued treatment due to adverse events, five of whom had decompensated cirrhosis.
05:16 EDTGILDGilead data supports ongoing trials evaluating shortened course of therapy
Subscribe for More Information
April 22, 2015
07:07 EDTGILD, ICPTEuropean Association for the Study of the Liver to hold annual meeting
50th Annual Meeting of EASL will be held in Vienna, Austria on April 22-26.
April 21, 2015
16:00 EDTGILDOptions Update; April 21, 2015
iPath S&P 500 VIX Short-Term Futures down 1c to 21.53 Option volume leaders: AAPL TSLA TWTR GILD FB PBR AMZN C KMI KO VZ MCD according to Track Data.
13:34 EDTGILDGilead paying premium to buy Vertex not warranted right now, says Maxim
After Bernstein suggested in a note to investors earlier that Gilead (GILD) should buy Vertex (VRTX), Maxim responded in its own note that it does not believe paying a premium to buy Vertex makes sense before the company has data showing efficacy for Kalydeco in heterozygotes. Maxim keeps a Hold rating and $121 price target on Vertex shares.
12:33 EDTGILDOn The Fly: Top stock stories at midday
Subscribe for More Information
12:21 EDTGILDVertex rises after Bernstein suggests Gilead should pursue takeover
Subscribe for More Information
10:00 EDTGILDGilead spikes higher, levels to watch
Subscribe for More Information
09:37 EDTGILDActive equity options trading on open
Subscribe for More Information
08:14 EDTGILDGilead should buy Vertex, says Bernstein
Subscribe for More Information
06:58 EDTGILDGilead May weekly volatility elevated into Q1 and outlook
Subscribe for More Information
April 20, 2015
09:36 EDTGILDActive equity options trading on open
Subscribe for More Information
07:20 EDTGILDAmerican Association for Cancer Research to hold annual meeting
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use